Curated Wealth Partners LLC Raises Holdings in Pfizer Inc. (NYSE:PFE)

Curated Wealth Partners LLC boosted its stake in Pfizer Inc. (NYSE:PFE) by 25.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 45,337 shares of the biopharmaceutical company’s stock after purchasing an additional 9,236 shares during the period. Curated Wealth Partners LLC’s holdings in Pfizer were worth $1,203,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of PFE. Exchange Traded Concepts LLC increased its stake in shares of Pfizer by 10.2% in the fourth quarter. Exchange Traded Concepts LLC now owns 76,250 shares of the biopharmaceutical company’s stock worth $2,023,000 after buying an additional 7,072 shares during the period. CX Institutional increased its position in shares of Pfizer by 9.1% in the fourth quarter. CX Institutional now owns 50,390 shares of the biopharmaceutical company’s stock valued at $1,337,000 after acquiring an additional 4,183 shares during the period. Sound Income Strategies LLC increased its position in shares of Pfizer by 10.0% in the fourth quarter. Sound Income Strategies LLC now owns 764,822 shares of the biopharmaceutical company’s stock valued at $20,291,000 after acquiring an additional 69,416 shares during the period. LexAurum Advisors LLC raised its stake in shares of Pfizer by 5.0% during the fourth quarter. LexAurum Advisors LLC now owns 28,112 shares of the biopharmaceutical company’s stock valued at $746,000 after acquiring an additional 1,326 shares during the last quarter. Finally, Neumann Capital Management LLC grew its stake in shares of Pfizer by 50.6% in the fourth quarter. Neumann Capital Management LLC now owns 22,588 shares of the biopharmaceutical company’s stock worth $599,000 after purchasing an additional 7,587 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Insider Activity at Pfizer

In other Pfizer news, Director Scott Gottlieb purchased 1,000 shares of the firm’s stock in a transaction dated Wednesday, October 30th. The stock was purchased at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the purchase, the director now directly owns 10,000 shares of the company’s stock, valued at $282,400. This trade represents a 11.11 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.06% of the stock is currently owned by insiders.

Pfizer Trading Down 1.3 %

Pfizer stock opened at $26.10 on Friday. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54. The company has a market capitalization of $147.89 billion, a price-to-earnings ratio of 35.27, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64. The business’s fifty day simple moving average is $26.08 and its two-hundred day simple moving average is $27.95. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. The company had revenue of $17.70 billion for the quarter, compared to analysts’ expectations of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. Pfizer’s revenue was up 31.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.17) EPS. As a group, equities analysts predict that Pfizer Inc. will post 2.94 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be issued a $0.43 dividend. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 dividend on an annualized basis and a yield of 6.59%. The ex-dividend date is Friday, January 24th. Pfizer’s payout ratio is presently 227.03%.

Analyst Upgrades and Downgrades

Several research firms have weighed in on PFE. Sanford C. Bernstein assumed coverage on Pfizer in a report on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price objective for the company. UBS Group dropped their price target on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research note on Wednesday, January 8th. Wolfe Research began coverage on shares of Pfizer in a research report on Friday, November 15th. They set an “underperform” rating and a $25.00 price objective on the stock. StockNews.com cut shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. Finally, Bank of America reiterated a “neutral” rating and set a $29.00 price target on shares of Pfizer in a research report on Tuesday, December 10th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Pfizer presently has an average rating of “Moderate Buy” and a consensus price target of $32.00.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.